Lantern Pharma (NASDAQ:LTRN) is a clinical-stage biopharmaceutical company innovating the repurposing, revitalization and development of precision therapeutics in oncology. We leverage advances in machine learning, genomics, and artificial intelligence by using a proprietary A.I. platform to discover biomarker signatures that help identify patients more likely to respond to our pipeline of cancer therapeutics. As of June 2021, this platform has collected approximately 5 billion data points.
Our current portfolio consists of four drug candidates and an anti-body drug conjugate (ADC) program across seven disclosed tumor targets, including two phase 2 programs and focuses on cancers that have unique and unmet clinical needs with a clearly defined patient population. We believe that the use of machine learning, genomics and computational methods can help accelerate drug discovery and development of small molecule-based therapies. By targeting drugs to patients whose genomic profile identifies them as having the highest probability of benefiting from the drug, this approach represents the potential to deliver best-in-class outcomes. Our team seeks out experienced industry partners, world-class scientific advisors, and innovative clinical-regulatory approaches to assist in delivering cancer therapies to patients as quickly and efficiently as possible.
CEO, President & Director
Panna Sharma has significant public and private experience in leading biotech, high-tech and emerging technology companies grow through a combination of organic mechanisms, internal alignment, capital-raising and strategic transactions. He is heavily focused on oncology, drug development, and the use of AI and machine learning to change the risk, cost and timeline in the highly interdisciplinary field of personalized medicine.